EP
SPRY icon

Essential Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Essential Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$264 Sell
33
-41
-55% -$353 ﹤0.01% 2596
2026
Q1 		$594 Buy
74
+70
+1,750% +$671 ﹤0.01% 2383
2025
Q4 		$47 Buy
+4
New +$39 ﹤0.01% 2642
2025
Q3 		– Sell
-57
Closed -$995 – 2778
2025
Q2 		$995 Buy
+57
New +$822 ﹤0.01% 1520

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Essential Partners's SPRY Position: Q2 2026 in Review

Essential Partners reduced its ARS Pharmaceuticals (SPRY) stake by 55% in Q2 2026, selling an estimated $353 and leaving 33 shares worth $264. The position accounts for ﹤0.01% of the portfolio, ranked #2596.

Essential Partners first reported a position in SPRY in Q2 2025 and has held it in 4 quarters since. The position peaked at $995 in Q2 2025. 206 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Essential Partners held 33 shares of ARS Pharmaceuticals worth $264 as of Q2 2026.
  • Essential Partners sold 41 ARS Pharmaceuticals shares in Q2 2026, an estimated $353.
  • ARS Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2596 holding.
  • Essential Partners first reported a position in ARS Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Essential Partners's ARS Pharmaceuticals position peaked at $995 in Q2 2025.
  • 206 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.